Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 THRIVE clinical trial of veligrotug (“veli”). Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody being developed for active thyroid eye disease/TED, which is an autoimmune condition that causes inflammation, growth, and damage to tissues around and behind the eye.
The THRIVE Phase 3 clinical trial in active TED evaluated 5 infusions of veligrotug or placebo administered every 3 weeks, with the primary topline analysis conducted at week 15, and patients followed through week 52. The new data reveal strong durability: 70% (21 out of 30) of veligrotug-treated patients in THRIVE who were proptosis responders at week 15 and continued follow-up to week 52, maintained their proptosis response.
A team of scientists in a laboratory examining a tube containing a monoclonal antibody.
The safety profile remained consistent during the follow-up period, with the vast majority of adverse events reported at the week 15 primary analysis having resolved by week 52. Veligrotug recently received Breakthrough Therapy Designation/BTD from the FDA, which supports its eligibility for Priority Review.
Viridian Therapeutics Inc. discovers, develops, and commercializes treatments for serious and rare diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
